Company intelligence / Profile preview

CuraSen Therapeutics

San Carlos, California, United Statescurasen.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CuraSen has multiple programs in clinical development. CuraAX (CST-3056) is in Phase 1 trials for neurogenic orthostatic hypotension. CuraCN (CST-103/CST-107) is advancing to Phase 2b for major depressive disorder. The company also has two Phase 2 studies in Alzheimer's disease using two distinct agonists (CST-103 and CST-2032).

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculesOral tablets
Industry: Biotech

Drug pipeline

5 assets

CST-2032

4 more assets in the full pipeline.

Request access →

Partnerships

Alzheimer's Drug Discovery Foundation

Beyond the preview

Go deeper on CuraSen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CuraSen Therapeutics.

Explore the full profile